I also researched some ways in targeting KRAS mutations. From the article titled, “‘Unexpected’ Vulnerability Creates Treatment Opportunity in Aggressive Type of Lung Cancer,” there has been studies done where XPO1 was used as an inhibitor. Since it was discovered that KRAS mutations rely on the protein, XPO1. Overall, it states that an XPO1 inhibitor would lead to a decrease in size of the tumor in NSCLC with KRAS mutations. Blocking XPO1’s activity lead to a disruption of the signaling pathway controlled by NFκB. NFκB is known to affects the activities genes involved in stimulating cell survival.